Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPN171H (Simmefafil) acute hemodynamics in pulmonary arterial hypertension
CTR20200874Phase 2Completed
- Sponsor
- Shandong Tefaman Pharmaceutical
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of simmefafil in pulmonary arterial hypertension (PAH), sponsored by Shandong Tefaman Pharmaceutical. Started Jul 2020; status: completed.
02
Drugs
simmefafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on CTR20200874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200874.